These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 12638138)

  • 1. [Epidemiological study on patients with pneumococcal respiratory tract infection in a Japanese health facility during the past year].
    Odagiri S; Watanuki Y; Takahashi H; Shimada J
    Jpn J Antibiot; 2001 May; 54 Suppl B():22-4; discussion 25-7. PubMed ID: 12638138
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparative study on bacterial eradication rate and clinical efficacy of CDTR, CFPN, and FRPM for treatment of children with otitis media and lower respiratory tract infection due to Streptococcus pneumoniae and Haemophilus influenzae].
    Sakata H
    Jpn J Antibiot; 2001 May; 54 Suppl B():96. PubMed ID: 12638154
    [No Abstract]   [Full Text] [Related]  

  • 3. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mid term report of the CDTR clinical trial for PRSP and BLNAR infections].
    Yokoyama M
    Jpn J Antibiot; 2001 May; 54 Suppl B():88-90. PubMed ID: 12638152
    [No Abstract]   [Full Text] [Related]  

  • 5. Ofloxacin in the treatment of lower respiratory tract infections: report of a prospective, comparative trial.
    Khajotia RR; Vetter N; Harazin H
    Clin Ther; 1991; 13(4):460-6. PubMed ID: 1933997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bacteriological aspects in the mid term report of the CDTR clinical trial for PRSP and BLNAR infections].
    Ubukata K
    Jpn J Antibiot; 2001 May; 54 Suppl B():91-5. PubMed ID: 12638153
    [No Abstract]   [Full Text] [Related]  

  • 7. The in vivo-in vitro paradox in pneumococcal respiratory tract infections.
    Bishai W
    J Antimicrob Chemother; 2002 Mar; 49(3):433-6. PubMed ID: 11864942
    [No Abstract]   [Full Text] [Related]  

  • 8. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
    Fuller JD; Low DE
    Clin Infect Dis; 2005 Jul; 41(1):118-21. PubMed ID: 15937772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacodynamic model to support a 12-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections.
    Bantar C; Nicola F; Fernandez Canigia L; Arenoso HJ; Soutric J; Montoto M; Blanco M; Smayevsky J; Jasovich A
    J Chemother; 2000 Jun; 12(3):223-7. PubMed ID: 10877517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibacterial therapy of pneumococcal infections caused by drug resistant microorganisms].
    Sidorenko SV
    Antibiot Khimioter; 2002; 47(7):31-7. PubMed ID: 12516194
    [No Abstract]   [Full Text] [Related]  

  • 11. [Discussions on PRSP and BLNAR].
    Tajima T; Meguro H; Akita H; Iwata T
    Jpn J Antibiot; 2001 May; 54 Suppl B():103; discussion 104-6. PubMed ID: 12638161
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic resistance patterns and serotype distribution in Streptococcus pneumoniae from hospitalized pediatric patients with respiratory infections in Suzhou, China.
    Chen R; Chen Y; Black S; Hao CL; Ding YF; Zhang T; Zhao GM
    J Trop Pediatr; 2010 Jun; 56(3):204-5. PubMed ID: 19748932
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cefditoren and community-acquired lower respiratory tract infections (corrected)].
    Barberán J; Mensa J
    Rev Esp Quimioter; 2009 Sep; 22(3):144-50. PubMed ID: 19662548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resisting the urge to prescribe.
    Edwards KM
    J Pediatr; 1996 Jun; 128(6):729-30. PubMed ID: 8648528
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isolation of bacteria and treatment of patients with pneumococcal and Haemophilus influenzae infections].
    Suzuki K
    Jpn J Antibiot; 2001 May; 54 Suppl B():97. PubMed ID: 12638155
    [No Abstract]   [Full Text] [Related]  

  • 18. Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae.
    Appelbaum PC
    Clin Infect Dis; 2000 Aug; 31 Suppl 2():S29-34. PubMed ID: 10984325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [beta-lactam-antibiotics in the treatment of community-acquired respiratory tract infections with penicillin-resistant pneumococci].
    Brauers J; Ewig S; Kresken M
    Pneumologie; 2002 Oct; 56(10):605-9. PubMed ID: 12375222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of the activity of cefditoren and comparator oral beta-lactam agents tested against community-acquired Streptococcus pneumoniae isolates (USA, 2004-2006).
    Fritsche TR; Biedenbach DJ; Jones RN
    J Chemother; 2008 Apr; 20(2):170-4. PubMed ID: 18467241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.